Buffet Dinner: 5:45 PM – 6:15 PM ET
Symposium: 6:15 PM – 7:45 PM ET
Omni Boston Hotel at the Seaport
450 Summer St
Boston, MA 02210
Ensemble Ballroom B
Program Overview
Childhood idiopathic nephrotic syndrome (INS), the most common pediatric glomerular disease, is associated with high treatment-related morbidity. Although most patients attain remission with corticosteroid therapy, a subset experience frequently relapsing NS (FRNS) or steroid-dependent NS (SDNS), creating a complex and challenging treatment scenario requiring consideration of steroid-sparing strategies that are not without adverse effects. This symposium will review current guidelines for FRNS and SDNS, examine emerging clinical trial data on anti-CD20 therapies—including rituximab and investigational agents such as obinutuzumab—and address real-world treatment challenges through clinical case scenarios presented by our expert faculty.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Outline the current guidelines for the treatment of FRNS and SDNS
- Analyze the latest clinical trial data for emerging anti-CD20 monoclonal antibody agents for the treatment of FRNS and SDNS
- Individualize treatment of FRNS and SDNS
Agenda
- Welcome and Introductions
- Overview of FRNS and SDNS: Diagnostic Criteria and Immunology of INS
- Treatment Challenges in INS Relapse: Applying Current Guidelines and Recommendations
- Steroid-Sparing Agents in FRNS and SDNS: Clinical Data and Practice Considerations
- Current and Emerging Anti-CD20 Therapies in FRNS and SDNS: Review of the Evidence
- Faculty Discussion and Conclusions
Learn More & Register: Advancements in Idiopathic Nephrotic Syndrome: Updates on Clinical Trial Data and Management
